NCT00148551

Brief Summary

A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jan 2004

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2004

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

September 6, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 8, 2005

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2008

Completed
Last Updated

July 30, 2007

Status Verified

July 1, 2007

First QC Date

September 6, 2005

Last Update Submit

July 26, 2007

Conditions

Age-Related Macular Degeneration

Keywords

AMDTriamcinoloneMacular Degeneration

Outcome Measures

Primary Outcomes (1)

  • Changes in visual acuity from baseline.

Secondary Outcomes (1)

  • Change in lesion characteristics from baseline.

Interventions

Triamcinolone AcetonideDRUG

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals with predominantly classic, subfoveal CNV secondary to AMD.
  • No previous PDT Treatment in study eye.

You may not qualify if:

  • CNV from conditions, other than AMD.
  • Other disease that could be responsible for decreased vision.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eye Care Centre

Vancouver, British Columbia, Canada

Location

Related Publications (1)

  • Maberley D; Canadian Retinal Trials Group. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology. 2009 Nov;116(11):2149-57.e1. doi: 10.1016/j.ophtha.2009.04.032. Epub 2009 Sep 12.

    PMID: 19748675DERIVED

MeSH Terms

Conditions

Macular Degeneration

Interventions

Triamcinolone Acetonide

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

TriamcinolonePregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • David A Maberley, M.D.

    University of British Columbia

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 6, 2005

First Posted

September 8, 2005

Study Start

January 1, 2004

Study Completion

March 1, 2008

Last Updated

July 30, 2007

Record last verified: 2007-07

Locations

CA(1)